ProMIS Neurosciences Inc.
Develops selective antibody therapeutics for neurodegenerative diseases.
PMN | US
Overview
Corporate Details
- ISIN(s):
- N/A
- LEI:
- Country:
- United States of America
- Address:
- SUITE 200, 1920 YONGE STREET, TORONTO
Description
ProMIS Neurosciences Inc. is a clinical-stage biotechnology company focused on the discovery and development of selective antibody therapeutics for neurodegenerative and other misfolded protein diseases. The company leverages a proprietary technology platform to design and generate antibodies that selectively target toxic oligomers, which are key drivers of diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), Parkinson’s disease (PD), and multiple system atrophy (MSA). Its lead product candidate, PMN310, is in clinical development for Alzheimer's disease. The company's approach aims to provide effective treatments while potentially reducing side effects associated with less specific therapies.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all ProMIS Neurosciences Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for ProMIS Neurosciences Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for ProMIS Neurosciences Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
